Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Three major uncertainties in the antibody therapy of cancer.

Stevenson GT.

Haematologica. 2014 Oct;99(10):1538-46. doi: 10.3324/haematol.2013.084640. Review.

2.

Follicular lymphoma and the immune system: from pathogenesis to antibody therapy.

Stevenson FK, Stevenson GT.

Blood. 2012 Apr 19;119(16):3659-67. doi: 10.1182/blood-2011-11-367730. Epub 2012 Feb 15.

PMID:
22337721
3.

A standardized conversion of IgG antibody to bispecific form with inversely altered affinities for Fcγ-receptors II and III.

Leong WS, Thomas KA, Chan CH, Stevenson GT.

Mol Immunol. 2011 Feb;48(5):760-8. doi: 10.1016/j.molimm.2010.11.019. Epub 2010 Dec 31.

PMID:
21196049
4.

CD38 as a therapeutic target.

Stevenson GT.

Mol Med. 2006 Nov-Dec;12(11-12):345-6.

6.

Engineered antibody for treating lymphoma.

Stevenson GT, Anderson VA, Leong WS.

Recent Results Cancer Res. 2002;159:104-12. Review.

PMID:
11785834
7.

Thioether-bonded constructs of Fab'gamma and Fc gamma modules utilizing differential reduction of interchain disulfide bonds.

Kan KS, Anderson VA, Leong WS, Smith AM, Worth AT, Stevenson GT.

J Immunol. 2001 Jan 15;166(2):1320-6.

8.

Preparation of fcgamma for addition to sulfhydryl-expressing ligands with minimal disturbance of the hinge.

Stevenson GT, Anderson VA, Leong WS.

J Immunol Methods. 1999 Dec 10;231(1-2):169-75.

PMID:
10648936
9.

Molecular markers of B-cell lymphoma.

Stevenson GT, Cragg MS.

Semin Cancer Biol. 1999 Apr;9(2):139-47. Review.

PMID:
10202135
10.

Immunotherapy of non-metastatic complication of malignant disease.

Stevenson GT.

Lancet. 1999 Jan 30;353(9150):340. No abstract available.

PMID:
9950433
11.

A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027.

Hawkins RE, Russell SJ, Marcus R, Ashworth LJ, Brissnik J, Zhang J, Winter G, Bleehen NM, Shaw MM, Williamson L, Ouwehand W, Stevenson F, Hamblin T, Oscier D, Zhu D, King C, Kumar S, Thompsett A, Stevenson GT.

Hum Gene Ther. 1997 Jul 1;8(10):1287-99. No abstract available.

PMID:
9215745
12.

Conjugation of human Fc gamma in closed-hinge or open-hinge configuration to Fab'gamma and analogous ligands.

Stevenson GT, Anderson VA, Kan KS, Worth AT.

J Immunol. 1997 Mar 1;158(5):2242-50.

PMID:
9036971
13.
14.

Chemical engineering at the antibody hinge.

Stevenson GT.

Chem Immunol. 1997;65:57-72. Review. No abstract available.

PMID:
9018872
15.

HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.

Elsässer D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, van de Winkel JG, Stevenson GT, Glennie MJ, Gramatzki M.

Blood. 1996 May 1;87(9):3803-12.

PMID:
8611706
16.

Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.

Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ, Stevenson GT, Crowe JS.

J Immunol. 1995 Jul 15;155(2):925-37.

PMID:
7608568
17.

Linkage of silver to antibodies through 2-imino thiolane.

Hazra DK, Stevenson GT, Kan KS.

Cell Biophys. 1995 Jun;26(3):183-6.

PMID:
8521450
18.

Design of trials for antibody treatment of tumour.

Stevenson GT.

Leuk Res. 1994 Jun;18(6):395-9. Review.

PMID:
8207956
19.

Mechanisms in removal of tumor by antibody.

Stevenson GT, Bell AJ, Evans TR, French RR, Glennie MJ, Hamblin TJ, Kan KS, Mead GM.

Cell Biophys. 1994;24-25:45-50.

PMID:
7736539
20.

The role of apoptosis in antibody-dependent cellular cytotoxicity.

Curnow SJ, Glennie MJ, Stevenson GT.

Cancer Immunol Immunother. 1993;36(3):149-55.

PMID:
8439975
21.

Subpopulations of guinea-pig T lymphocytes defined by isoforms of the leucocyte common antigen.

Hart IJ, Schäfer H, Scheper RJ, Stevenson GT.

Immunology. 1992 Nov;77(3):377-84.

22.

Cytoplasmic calcium fluxes induced in cytotoxic effector cells by engagement of Fc gamma receptors I, II, and III.

Curnow SJ, Glennie MJ, Stevenson GT.

Scand J Immunol. 1992 Aug;36(2):221-31.

PMID:
1386938
23.
25.

Bispecific F(ab'gamma)3 antibody derivatives for redirecting unprimed cytotoxic T cells.

Tutt A, Greenman J, Stevenson GT, Glennie MJ.

Eur J Immunol. 1991 Jun;21(6):1351-8.

PMID:
1828423
26.

Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.

French RR, Courtenay AE, Ingamells S, Stevenson GT, Glennie MJ.

Cancer Res. 1991 May 1;51(9):2353-61.

27.

Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.

Urch CE, George AJ, Stevenson GT, Bolognesi A, Stirpe F, Weller R, Glennie MJ.

Int J Cancer. 1991 Apr 1;47(6):909-15.

PMID:
2010234
28.

Enhanced modulation of antibodies coating guinea pig leukemic cells in vitro and in vivo. The role of Fc gamma R expressing cells.

Lane AC, Foroozan S, Glennie MJ, Kowalski-Saunders P, Stevenson GT.

J Immunol. 1991 Apr 1;146(7):2461-8.

PMID:
1826021
29.

Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.

Stevenson FK, Bell AJ, Cusack R, Hamblin TJ, Slade CJ, Spellerberg MB, Stevenson GT.

Blood. 1991 Mar 1;77(5):1071-9.

PMID:
1995092
30.

Attack on neoplastic cell membranes by therapeutic antibody.

Stevenson GT.

Mol Cell Biochem. 1989 Nov 23-Dec 19;91(1-2):33-8.

PMID:
2622456
31.

A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge.

Stevenson GT, Pindar A, Slade CJ.

Anticancer Drug Des. 1989 Mar;3(4):219-30.

PMID:
2930624
32.

Use of anti-idiotypic antibodies to treat lymphoid tumors.

Stevenson GT.

Methods Enzymol. 1989;178:341-55. No abstract available.

PMID:
2481211
33.

Lymphokine-activated killer cells from normal and lymphoma subjects are cytotoxic for cells coated with antibody derivatives displaying human Fc gamma.

Dearman RJ, Stevenson FK, Wrightham M, Hamblin TJ, Glennie MJ, Stevenson GT.

Blood. 1988 Dec;72(6):1985-91.

PMID:
2973819
34.

Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.

Glennie MJ, Brennand DM, Bryden F, McBride HM, Stirpe F, Worth AT, Stevenson GT.

J Immunol. 1988 Nov 15;141(10):3662-70.

PMID:
3141503
35.

Idiotypes and anti-idiotypes in myeloma.

Stevenson GT, Thompson J.

Hematol Oncol. 1988 Apr-Jun;6(2):103-6. No abstract available.

PMID:
3260574
36.

Problems and prospects in the use of lymphoma idiotypes as therapeutic targets.

Stevenson GT, Glennie MJ, Hamblin TJ, Lane AC, Stevenson FK.

Int J Cancer Suppl. 1988;3:9-12.

PMID:
3209307
37.

Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.

Glennie MJ, McBride HM, Worth AT, Stevenson GT.

J Immunol. 1987 Oct 1;139(7):2367-75.

PMID:
2958547
38.

Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin.

Glennie MJ, McBride HM, Stirpe F, Thorpe PE, Worth AT, Stevenson GT.

J Exp Med. 1987 Jul 1;166(1):43-62.

39.

Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody.

Hamblin TJ, Cattan AR, Glennie MJ, MacKenzie MR, Stevenson FK, Watts HF, Stevenson GT.

Blood. 1987 Mar;69(3):790-7.

PMID:
3101763
40.

Monoclonal anti-light chain idiotype as a tumor-specific probe for human neoplastic B lymphocytes.

Wrightham M, Tutt AL, Glennie MJ, Hamblin TJ, Stevenson GT, Stevenson FK.

Blood. 1987 Mar;69(3):919-23.

PMID:
2434161
41.

Analysis of the interaction of antibodies with immunoglobulin idiotypes on neoplastic B lymphocytes: implications for immunotherapy.

Elliott TJ, Glennie MJ, McBride HM, Stevenson GT.

J Immunol. 1987 Feb 1;138(3):981-8.

PMID:
2433338
42.

Involvement of innate and induced anti-idiotypic mechanisms in suppression of B cell tumors.

Stevenson FK, George AJ, Tutt AL, Glennie MJ, Stevenson GT.

Monogr Allergy. 1987;22:184-93. No abstract available.

PMID:
3501833
43.

Antibodies to shared idiotypes as agents for analysis and therapy for human B cell tumors.

Stevenson FK, Wrightham M, Glennie MJ, Jones DB, Cattan AR, Feizi T, Hamblin TJ, Stevenson GT.

Blood. 1986 Aug;68(2):430-6.

PMID:
2425869
44.

Therapeutic strategies for B cell malignancies involving idiotype-anti-idiotype interactions.

Stevenson FK, Stevenson GT.

Int Rev Immunol. 1986 Jul;1(3-4):303-33. Review.

PMID:
3334051
45.

The prospects for treating cancer with antibody.

Stevenson GT.

Sci Prog. 1986;70(280 Pt 4):505-19. No abstract available.

PMID:
3749860
46.

Preparation and properties of FabIgG, a chimeric univalent antibody designed to attack tumour cells.

Stevenson GT, Glennie MJ, Paul FE, Stevenson FK, Watts HF, Wyeth P.

Biosci Rep. 1985 Oct-Nov;5(10-11):991-8.

PMID:
3879458
47.

Activation of complement pathways by univalent antibody derivatives with intact Fc zones.

Watts HF, Anderson VA, Cole VM, Stevenson GT.

Mol Immunol. 1985 Jul;22(7):803-10.

PMID:
3849671
48.

Secretion of idiotypic IgM by the mouse B-cell leukaemia (BCL1) occurs spontaneously in vitro and in vivo.

Tutt AL, Stevenson FK, Slavin S, Stevenson GT.

Immunology. 1985 May;55(1):59-63.

49.

Surface immunoglobulin of B-lymphocytic tumours as a therapeutic target.

Stevenson GT, Glennie MJ.

Cancer Surv. 1985;4(1):213-44. Review.

PMID:
3916080
50.

Derivatives of anti-idiotype antibodies in the treatment of B-cell lymphoma.

Glennie MJ, Stevenson GT.

Adv Exp Med Biol. 1985;186:843-53. No abstract available.

PMID:
3876727

Supplemental Content

Loading ...
Support Center